<DOC>
	<DOCNO>NCT01519687</DOCNO>
	<brief_summary>The purpose study determine whether levotofisopam safe effective treatment hyperuricemia gout .</brief_summary>
	<brief_title>Study Levotofisopam 50 mg Three Times Day ( TID ) Administered 7 Days Hyperuricemia Gout</brief_title>
	<detailed_description>The primary objective study ( 1 ) evaluate safety tolerability levotofisopam patient hyperuricemia gout , ( 2 ) evaluate effect treatment levotofisopam serum urate level patient .</detailed_description>
	<mesh_term>Gout</mesh_term>
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Tofisopam</mesh_term>
	<criteria>Provide voluntary , sign informed consent . Male postmenopausal surgically sterile female , 18 65 year age , inclusive . Female participant must amenorrheic minimum 12 month must negative pregnancy test result within 3 day administration levotofisopam . Surgically sterile female define hysterectomy , bilateral ovariectomy , bilateral tubal ligation . Male subject must agree practice medically acceptable form contraception duration study 30 day receive last dose levotofisopam . Physician diagnosis gout least one gout flare last 6 month , least one chronically swollen joint due gout , presence tophus . Serum urate level ≥ 8.0 mg/dL ≤ 12.0 mg/dL stop uratelowering therapy least 10 day . Serum urate level must also &gt; 7.7 mg/dL ≤ 12.0 mg/dL Day 3 Day 2 . Willing able discontinue uratelowering therapy start screen visit ( 1421 day receive study drug ) followup visit ( 10 day discharge study unit ) , total time uratelowering therapy approximately 5 week . In opinion investigator , able participate schedule evaluation , likely complete require test , likely compliant . Medications permit treatment nonexcluded medical condition ( gout ) must stable dos least 14 day prior baseline . Permitted concurrent general medical condition must stable well control . Written oral fluency English language . Previous treatment racemic tofisopam ( RStofisopam ) , levotofisopam ( Stofisopam ) , dextofisopam ( Rtofisopam ) . Known suspected hypersensitivity benzodiazepine . History two clinically significant drug allergy . Clinically significant infection within 30 day prior screen screen admission . History presence clinically significant medical disease might compromise study detrimental patient , hepatitis ( patient exclude hepatitis A present within 2 year screen history hepatitis B C ) , human immunodeficiency virus ( HIV ) infection , uncontrolled diabetes mellitus , cirrhosis , active biliary disease ( bile duct gallbladder ) , moderate severe chronic kidney disease ( estimate glomerular filtration rate &lt; 60 mL/min/1.73 m2 ) . Presence gout flare screen procedure window . History presence nephrolithiasis . History presence malignancy localize basal cell cancer , squamous cell skin cancer , cancer situ resect within 5 year . Clinically significant head trauma loss consciousness within 10 year prior screen . Myocardial infarction , congestive heart failure , know coronary artery disease within 5 year prior screen . Any history cerebrovascular accident . History seizure disorder single childhood febrile seizure . Alcohol psychoactive substance abuse dependence , define DSMIV , within 1 year prior screen , alcohol use exceed 21 unit per week ( average ) 3 month precede screen . Used tobacco nicotinecontaining product day within 30 day prior screen screen admission . Regular consumption ( e.g. , day ) excessive quantity caffeinecontaining beverage ( e.g. , eight cup coffee equivalent per day ) within 30 day prior screen screen admission . History suicide attempt , suicidal behavior within 6 month prior screen screen baseline , , opinion investigator , clinically significant risk suicide violent behavior . History presence clinically significant psychiatric disorder symptom ( e.g. , delusion , hallucination ) likely compromise study ( e.g. , confound study result ) detrimental patient . History difficulty donate blood , history presence clinically significant bleed hemorrhagic tendency . Donation blood plasma within 90 day prior screen screen admission . Uncontrolled hypertension ( systolic blood pressure &gt; 160 mmHg and/or diastolic &gt; 95 mmHg ) heart rate either &lt; 50 BPM &gt; 100 BPM evaluation prior first dose test drug . Pregnancy , lactation , positive pregnancy test result screen admission evaluation . A clinically significant abnormality screen physical examination , 12lead electrocardiogram ( ECG ) , laboratory evaluation . A correct QT ( QTcF ) value &gt; 450 msec ( male ) &gt; 470 msec ( female ) screening , admission ( Day 3 ) , baseline ( Day 1 ) . Aspartate aminotransferase alanine aminotransferase level &gt; 2 time upper limit normal ( ULN ) , alkaline phosphatase &gt; 1.5 time ULN , creatinine outside limit normal , triglyceride &gt; 500 mg/dL , thyroidstimulating hormone ( TSH ) level great 6.0 µIU/L screening , admission ( Day 3 ) , Day 2 . A finding opiates , amphetamine , cocaine , cannabis , phencyclidine urine drug screen ( UDS ) . Any positive UDS result must discuss investigator medical monitor prior potentially allow participation subject study . A positive HIV , hepatitis B , hepatitis C test . Inability take tolerate colchicine gout flare prophylaxis ( 0.6 mg QD BID ) . Required use follow screen visit followup visit : aspirin nonsteroidal antiinflammatory drug ( paracetamol , note ) , diuretic , medication know uratelowering effect ( include , limited , fenofibrate , losartan , vitamin C &gt; 500 mg/day ) , uratelowering therapy levotofisopam . Dietary requirement inconsistent study unit 's standardized diet . Body mass index ≥ 35 . Use investigational treatment within 30 day prior screen screen admission . Use psychopharmacologic drug substance within 7 day screen screen admission . Use potent CYP3A4 inhibitor potent CYP3A4 inducer within 7 day prior screen screen admission . An estimated 24hour uric acid excretion &gt; 1,000 mg/day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>hyperuricemia</keyword>
	<keyword>gout</keyword>
	<keyword>levotofisopam</keyword>
</DOC>